BioCentury | Jun 22, 2019
Clinical News

June 21 Clinical Quick Takes: Melanoma miss for Exelixis/Genentech combo; plus Progenics, Turning Point, Gracell

...Point Sinks on ASCO Update" ). CPP to pursue approval of FAP combo despite miss Cancer Prevention Pharmaceuticals Inc....
...CPP-1X/sul, CPP-1X/sulindac) repotrectinib (TPX-0005) Tecentriq (Brand), RG7446 (Compound #), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) Cancer Prevention Pharmaceuticals Inc. Exelixis...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

.../ Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) Zydis rimegepant Treat acute migraine Submit NDA 2Q19 Cancer Prevention Pharmaceuticals Inc....
BioCentury | Jan 5, 2018
Company News

Mallinckrodt acquiring Sucampo

...Phase III trial to treat familial adenomatous polyposis (FAP). The candidate is being developed with Cancer Prevention Pharmaceuticals Inc....
BioCentury | Dec 26, 2017
Company News

Mallinckrodt acquiring Sucampo

...Phase III trial to treat familial adenomatous polyposis (FAP). The candidate is being developed with Cancer Prevention Pharmaceuticals Inc....
BioCentury | Jul 28, 2017
Clinical News

Cancer Prevention starts Phase II of CPP-1x to prevent gastric cancer

...eflornithine (difluoromethylornithine, DFMO), a selective inhibitor of ornithine decarboxylase (ODC), and sulindac, a generic NSAID. Cancer Prevention Pharmaceuticals Inc....
...damage at 18 months, gastritis histopathology score and safety Status: Phase II started Milestone: NA Alicia Parker CPP-1X Cancer Prevention Pharmaceuticals Inc....
BioCentury | Jun 23, 2017
Clinical News

IDMC recommends continuation of Cancer Prevention's Phase III FAP trial

...exclusively develop and commercialize the product in North America (see BioCentury, Feb. 1, 2016 ). Cancer Prevention Pharmaceuticals Inc....
...an ODC polymorphism and excretion of 4 urinary polyamines Status: Phase III ongoing Milestone: NA Meghan Sullivan CPP-1X/sulindac DFMO/sulindac eflornithine/sulindac Cancer Prevention Pharmaceuticals Inc. Sucampo...
BioCentury | Apr 7, 2017
Finance

Right place, right time

...drug Amitiza lubiprostone, and an option to a combination of CPP-1X (eflornithine) and sulindac from Cancer Prevention Pharmaceuticals Inc....
BioCentury | Nov 4, 2016
Financial News

Cancer Prevention Pharmaceuticals withdraws IPO

...conditions. Last December, it filed to raise up to $28.8 million. Cancer Prevention Pharmaceuticals Inc. , Tucson, Ariz. Alex Himes Cancer Prevention Pharmaceuticals Inc....
BioCentury | Oct 3, 2016
Finance

Reasonable rally

...C) 3/9/16 TBD Mkt (tools & services) Visterra Inc. 1/5/16 Up to $69M Ph II Cancer Prevention Pharmaceuticals Inc....
BioCentury | Jul 28, 2016
Distillery Therapeutics

Therapeutics: Spermidine/spermine N1-acetyltransferase 1 (SAT1; SSAT); ornithine decarboxylase (ODC)

...S.A. and Cipher Pharmaceuticals Inc. market Vaniqa eflornithine to treat unwanted facial hair in women. Cancer Prevention Pharmaceuticals Inc....
Items per page:
1 - 10 of 31
BioCentury | Jun 22, 2019
Clinical News

June 21 Clinical Quick Takes: Melanoma miss for Exelixis/Genentech combo; plus Progenics, Turning Point, Gracell

...Point Sinks on ASCO Update" ). CPP to pursue approval of FAP combo despite miss Cancer Prevention Pharmaceuticals Inc....
...CPP-1X/sul, CPP-1X/sulindac) repotrectinib (TPX-0005) Tecentriq (Brand), RG7446 (Compound #), MPDL3280A (Compound #), atezolizumab (Generic), Tecentriq (Other), Anti-PDL1 (Other) Cancer Prevention Pharmaceuticals Inc. Exelixis...
BioCentury | Apr 6, 2019
Finance

Big caps under pressure

.../ Biohaven Pharmaceutical Holding Co. Ltd. (NYSE:BHVN) Zydis rimegepant Treat acute migraine Submit NDA 2Q19 Cancer Prevention Pharmaceuticals Inc....
BioCentury | Jan 5, 2018
Company News

Mallinckrodt acquiring Sucampo

...Phase III trial to treat familial adenomatous polyposis (FAP). The candidate is being developed with Cancer Prevention Pharmaceuticals Inc....
BioCentury | Dec 26, 2017
Company News

Mallinckrodt acquiring Sucampo

...Phase III trial to treat familial adenomatous polyposis (FAP). The candidate is being developed with Cancer Prevention Pharmaceuticals Inc....
BioCentury | Jul 28, 2017
Clinical News

Cancer Prevention starts Phase II of CPP-1x to prevent gastric cancer

...eflornithine (difluoromethylornithine, DFMO), a selective inhibitor of ornithine decarboxylase (ODC), and sulindac, a generic NSAID. Cancer Prevention Pharmaceuticals Inc....
...damage at 18 months, gastritis histopathology score and safety Status: Phase II started Milestone: NA Alicia Parker CPP-1X Cancer Prevention Pharmaceuticals Inc....
BioCentury | Jun 23, 2017
Clinical News

IDMC recommends continuation of Cancer Prevention's Phase III FAP trial

...exclusively develop and commercialize the product in North America (see BioCentury, Feb. 1, 2016 ). Cancer Prevention Pharmaceuticals Inc....
...an ODC polymorphism and excretion of 4 urinary polyamines Status: Phase III ongoing Milestone: NA Meghan Sullivan CPP-1X/sulindac DFMO/sulindac eflornithine/sulindac Cancer Prevention Pharmaceuticals Inc. Sucampo...
BioCentury | Apr 7, 2017
Finance

Right place, right time

...drug Amitiza lubiprostone, and an option to a combination of CPP-1X (eflornithine) and sulindac from Cancer Prevention Pharmaceuticals Inc....
BioCentury | Nov 4, 2016
Financial News

Cancer Prevention Pharmaceuticals withdraws IPO

...conditions. Last December, it filed to raise up to $28.8 million. Cancer Prevention Pharmaceuticals Inc. , Tucson, Ariz. Alex Himes Cancer Prevention Pharmaceuticals Inc....
BioCentury | Oct 3, 2016
Finance

Reasonable rally

...C) 3/9/16 TBD Mkt (tools & services) Visterra Inc. 1/5/16 Up to $69M Ph II Cancer Prevention Pharmaceuticals Inc....
BioCentury | Jul 28, 2016
Distillery Therapeutics

Therapeutics: Spermidine/spermine N1-acetyltransferase 1 (SAT1; SSAT); ornithine decarboxylase (ODC)

...S.A. and Cipher Pharmaceuticals Inc. market Vaniqa eflornithine to treat unwanted facial hair in women. Cancer Prevention Pharmaceuticals Inc....
Items per page:
1 - 10 of 31